1 Multimorbidity and blood pressure control: a cross-sectional analysis among 67,385 adults with

2 hypertension in Canada

- 3 Short title: Multimorbidity and blood pressure control in primary care
- 4 Tu N Nguyen^{1,2}, Sumeet Kalia², Peter Hanlon³, Bhautesh D Jani³, Barbara I Nicholl³, Chelsea D.
- 5 Christie², Babak Aliarzadeh², Rahim Moineddin², Christopher Harrison⁴, Clara Chow¹, Martin
- 6 Fortin⁵, Frances S Mair³, Michelle Greiver^{2,6}

- 8 ¹ Westmead Applied Research Centre, Sydney Medical School, Faculty of Medicine and Health,
- 9 University of Sydney, Sydney, New South Wales, Australia.
- 10 ² Department of Family and Community Medicine, Temerty Faculty of Medicine, University of
- 11 Toronto, Toronto, ON, Canada
- ³ General Practice and Primary Care, School of Health and Wellbeing, University of Glasgow, UK
- ⁴ Menzies Centre for Health Policy and Economics, School of Public Health, Faculty of Medicine and
- 14 Health, University of Sydney, Sydney, New South Wales, Australia
- ⁵ Department of family medicine and emergency medicine, Université de Sherbrooke, Saguenay, QC,
 Canada
- ⁶ Department of Family and Community Medicine, North York General Hospital, Toronto, ON,
- 18 Canada
- 19
- 20
- 21
- 22
- 23

24

25 Abstract

Background. There has been conflicting evidence on the association between multimorbidity and blood pressure (BP) control. This study aimed to investigate this associations in people with hypertension attending primary care in Canada, and to assess whether individual long-term conditions are associated with BP control.

30 Methods. A cross-sectional study in people with hypertension attending primary care in Toronto 31 between January 01 2017 and December 31 2019. Uncontrolled BP was defined as systolic BP≥140 32 mmHg or diastolic BP≥90 mmHg. A list of 11 a priori selected chronic conditions was used to define 33 multimorbidity. Multimorbidity was defined as having ≥1 long-term condition in addition to 34 hypertension. Logistic regression models were used to estimate the association between 35 multimorbidity (or individual long-term conditions) with uncontrolled BP.

36 **Results.** A total of 67,385 patients with hypertension were included. They had a mean age of 70, 37 53.1% were female, 80.6% had multimorbidity, and 35.7% had uncontrolled BP. Patients with 38 multimorbidity had lower odds of uncontrolled BP than those without multimorbidity (adjusted OR 39 0.72, 95% CI 0.68-0.76). Among the long-term conditions, diabetes (aOR 0.73, 95%CI 0.70-0.77), heart failure (aOR 0.81, 95%CI 0.73-0.91), ischemic heart disease (aOR 0.74, 95%CI 0.69-0.79), 40 schizophrenia (aOR 0.79, 95%CI 0.65-0.97), depression/anxiety (aOR 0.91, 95%CI 0.86-0.95), 41 42 dementia (aOR 0.87, 95%CI 0.80-0.95), and osteoarthritis (aOR 0.89, 95%CI 0.85-0.93) were 43 associated with a lower likelihood of uncontrolled BP.

44 Conclusion. We found that multimorbidity was associated with better BP control. Several conditions
45 were associated with better control, including diabetes, heart failure, ischemic heart disease,
46 schizophrenia, depression/anxiety, dementia, and osteoarthritis.

- 47 Keywords: hypertension, high blood pressure, blood pressure control, multimorbidity, primary care
- 48

49 Introduction

50 Hypertension is a risk factor for cardiovascular disease and other chronic health conditions. The prevalence of hypertension increases with age, with a prevalence of only 27% in people younger than 51 60 years, but 74% in people aged 80 and older.¹ Globally, blood pressure (BP) control is still 52 suboptimal, with control rates of only approximately 20% for people with hypertension.² Poor control 53 54 of hypertension can increase the risk of heart failure, coronary heart disease, peripheral artery disease, 55 renal failure, stroke and dementia, and therefore, increase the risk of developing multimorbidity in people with hypertension.³ Multimorbidity, defined as having two or more chronic conditions, has 56 become a primary healthcare concern.^{4,5} 57

Two out of three people with hypertension have additional long-term condition.⁶ A systematic review of 45 studies conducted from 2007 to 2017 showed that the overall prevalence of multimorbidity was 66.1% (when multimorbidity was defined as having \ge 2 chronic conditions), and 44.2% (when multimorbidity was defined as having \ge 3 chronic conditions) in older adults in highincome countries.⁷ In the United States, 81 million adults were estimated to have multimorbidity in 2020.⁸ In Canada, the prevalence of multimorbidity is also high, with a reported prevalence ranging from around 30% to 70% in primary care settings, and around 17% to 59% in the general population.⁹

65 Multimorbidity increases healthcare costs and healthcare utilisation including hospitalisations.^{10,11}

Several studies have examined the impact of multimorbidity on BP control, and there has been 66 conflicting evidence on the association between multimorbidity and hypertension control.¹²⁻¹⁷ While 67 some studies show that the presence of multimorbidity was positively associated with BP 68 control,^{12,16,18} other studies suggested that people with more comorbidities had poorer management 69 and control of hypertension.^{15,17} There is minimal evidence of this association in the Canadian 70 71 population. Therefore, in this study, we aimed to investigate the association between multimorbidity 72 and BP control in patients attending primary care in Canada, and to assess if individual comorbidities 73 are associated with BP control.

75 Materials and Methods

76 Data source

- 77 This study used data from the University of Toronto Practice-Based Research Network (UTOPIAN),
- 78 a primary care electronic medical records (EMRs) database. The UTOPIAN database contains de-
- 79 identified records from participating family medicine clinics in Ontario, Canada, with most providers
- 80 practicing in the Greater Toronto Area.¹⁹ Data include de-identified patient-level information on
- 81 various factors including demographics, medical diagnoses, procedures, medications, immunizations,
- 82 laboratory test results, vital signs, risk factors, and clinical notes.

83 Study design and eligible patients

- 84 This is a cross-sectional study using the UTOPIAN 2021Q4 database with a start date of January 01
- 85 2017 and an end date of December 31 2019. This end date was chosen to avoid the COVID-19
- pandemic-related effects on the data. The data were accessed for research purposes from June 17 2022
- to December 16 2022. We identified a cohort of patients who met the following selection criteria; had
- 88 hypertension before December 31 2019; had blood pressure recorded between Jan 01 2017 and Dec
- 89 31 2019; and were at least 45 years old when their blood pressure was measured. Figure 1 provides a
- 90 flowchart for the cross-sectional cohort.
- 91 We defined the hypertension phenotype using the following criteria (Appendix 2):
- 92 1. Free text documentation of hypertension was found within the (past or present) health
- 93 condition section of the cumulative patient profile, including the following terms:
- 94 hypertension, hypertensive, htn; OR
- 95 2. Anti-hypertensive medication was prescribed and an elevated blood pressure reading was
 96 recorded at any point in the EMR (elevated blood pressure reading is defined as systolic blood
 97 pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); OR
- 98 3. Anti-hypertensive medication was prescribed and a billing record with the diagnosis code for
 99 hypertension (ICD-9 code 401) was recorded at any point in the EMR; OR

100	4.	A billing record with the diagnosis code for hypertension (ICD-9 code 401) and an elevated
101		blood pressure reading was recorded at any point in the EMR (elevated blood pressure
102		reading is defined as systolic blood pressure \geq 140 mmHg or diastolic blood pressure \geq 90

103 mmHg)

104 Multimorbidity

105 Multimorbidity was defined as having one or more long-term conditions in addition to hypertension. This definition of multimorbidity is similar to definitions used in other studies (REFs).²⁰⁻²² A list of 11 106 107 a priori selected chronic conditions was used to define multimorbidity, in alignment with the Centers 108 for Disease Control and Prevention (CDC) recommendations for defining and measuring multiple chronic conditions when using Medicare claims.²³ These long-term condition are: ischemic heart 109 110 disease, heart failure, atrial fibrillation, diabetes, chronic obstructive pulmonary disease, asthma, 111 chronic kidney disease (chronic kidney disease stage 3 or more, or dependence on transplant or 112 dialysis), cancers (including breast cancer, cervical cancer, lung cancer, colorectal cancer, ovarian 113 cancer, pancreatic cancer, prostate cancer, thyroid cancer), osteoarthritis, dementia, depression and/or 114 anxiety, and schizophrenia.

115 *Covariate definitions*

116 We used the most recent information on Body Mass Index (BMI) and smoking status as of December

117 31, 2019. BMI was grouped into underweight (≤18.4), normal (18.5-24.9), overweight (25.0-29.9),

118 obese class I (30.0-34.9), obese class II (35.0-39.9), and obese class III (≥40.0). We calculated age (in

119 years) on the date when the blood pressure measurement was recorded between January 01, 2017 and

120 December 31, 2019. We used rurality and neighbourhood income quintiles (as an indicator of

121 socioeconomic status) using data from the 2016 Statistics Canada Census.²⁴

122 We identified different classes of hypertension medication (including angiotensin converting enzyme

123 inhibitors (ACEi), angiotensin II receptor blocker (ARBi), calcium channels, beta-blockers, diuretics,

124 and other classes of hypertension medication) that were prescribed during the six months prior to the

125 blood pressure measurement. The full description of drug names for each class of hypertension

126 medication is provided in Appendix section (i), along with the algorithm used to determine the

- 127 presence of hypertension in EMRs (see Appendix section (ii)).
- 128 *Outcome measure*
- 129 The primary outcome measurement was the most recent BP measure recorded during the study period
- 130 (January 01, 2017 to December 31, 2019). Uncontrolled BP was defined as having either systolic
- 131 blood pressure \geq 140 mmHg or diastolic blood pressure \geq 90 mmHg for the last BP measurement prior
- to December 31 2019. The BP treatment target was chosen to align with the Hypertension Canada's
- 133 2016 Canadian hypertension education program guidelines for blood pressure measurement,
- diagnosis, assessment of risk, prevention, and treatment of hypertension that reflected the practice
- during the study period 25 The SBP treatment goal is a pressure level of < 140 mm Hg (Grade C). The
- 136 DBP treatment goal is a pressure level of < 90 mm Hg (Grade A). These targets were established
- 137 using Office-based BP Measurements (OBPM).²⁵ For patients with multiple BP readings recorded on
- the same day at the same visit (e.g. using an automated BPtru machine), we took the average
- 139 measurement of the systolic and diastolic blood pressure measures on that day.
- 140 We also conducted a sensitivity analysis, with a BP target of < 130/80 mmHg, as recommended by
- the 2018 ESC/ESH Guidelines for the management of arterial hypertension²⁶, and the 2017
- 142 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,
- 143 Detection, Evaluation, and Management of High Blood Pressure in Adults.²⁷
- 144 Statistical analysis
- 145 We used descriptive statistics to summarize patient demographics and clinical characteristics
- 146 associated with controlled and uncontrolled blood pressure. We used means, standard deviations, and
- 147 median, minimum and maximum to summarize continuous variables, while frequencies and
- 148 percentages were used to summarize categorical variables. To reduce the risk of re-identification, our
- 149 reports exclude any cell count of five or fewer. Comparisons between patients with controlled and
- 150 uncontrolled BP were assessed using Pearson chi-square tests for categorical covariates and using
- 151 two-sample t-tests for continuous covariates.

152 We fitted logistic regression models using the Generalized Estimating Equations (GEE) with an 153 exchangeable working correlation matrix to assess the association between multimorbidity (or 154 individual long-term condition) on uncontrolled BP. We reported both the unadjusted odds ratios and 155 adjusted odds ratios. To account for multicollinearity, we fitted separate logistic models using GEE 156 for multimorbidity and different comorbidities, respectively. We a priori specified age, sex, income 157 quintiles, smoking BMI as potential confounders (i.e. common cause) for multimorbidity and for the 158 outcome of BP control, while different classes of hypertension medications were considered potential 159 mediators on the pathway between multimorbidity and BP control (see Supplementary Figure S1). In 160 GEE models, we adjusted for the following covariates: age, sex, income quintiles, smoking status, 161 BMI, number of primary care visits, along with the multimorbidity status. 162 In a sensitivity analysis, we used a reduced threshold for blood pressure control (<130/80 mm Hg) and 163 excluded BMI and smoking status in the regression models to include patients that did not have BMI 164 or smoking status recorded. 165 Ethics approval 166 This study was approved by the Research Ethics Board at the University of Toronto (protocol number

167 00043354).

168 Results

169 Sample characteristics

A total of 67,385 patients who satisfied the selection criteria were included in this study. Patients in the sample had a mean age of 70.1 years (SD 11.8) and 53.1% were female. The prevalence of overweight and obesity was 66%, with a greater proportion of patients with class II and class III obesity in the uncontrolled BP group compared to the controlled BP group. There was no difference in socioeconomic status between the two groups. (**Table 1**)

175 Multimorbidity

- 176 The overall prevalence of multimorbidity was 80.6%. Patients with multimorbidity had a higher
- 177 number of annual primary care visits than patients without multimorbidity in 2017, 2018 and 2019
- 178 (Supplementary Table S2). As an example, 8.0% of the patients with multimorbidity had more than
- 179 9 visits in 2019 compared to 1.9% of patients without multimorbidity
- 180 Uncontrolled blood pressure
- 181 Overall, 35.7% of patients had uncontrolled BP (34.1% in patients with multimorbidity and 42.7% in
- patients without multimorbidity, p<0.001). Figure 2 presents the percentages of uncontrolled BP in
- 183 patients with and without multimorbidity. Across the three age groups, patients with multimorbidity
- 184 had lower rates of uncontrolled BP compared to patients without multimorbidity.
- 185 The association between multimorbidity and hypertension control
- 186 Patients with multimorbidity had lower odds of uncontrolled BP compared to those without
- multimorbidity (adjusted OR = 0.72, 95% CI 0.68 to 0.76, adjusted for age, sex, income quintiles,
- smoking status, body mass index, and number of visits). Younger patients had lower odds of having
- uncontrolled BP than older patients. Obese patients (in class I, II and III) had higher odds of
- 190 uncontrolled BP than those with normal BMI. Current smokers had higher odds of having
- 191 uncontrolled BP compared to non-smokers. Increasing number of visits to primary care doctors was
- associated with lower odds of uncontrolled BP. (Figure 3)

193

194 The association between types of long-term conditions and hypertension control

- 195 Among the long-term conditions, seven conditions were significantly associated with lower likelihood
- of uncontrolled BP: diabetes (adjusted OR 0.73, 95%CI 0.70-0.77), heart failure (adjusted OR 0.81,
- 197 95%CI 0.73-0.91), ischemic heart disease (adjusted OR 0.74, 95%CI 0.69-0.79), schizophrenia
- 198 (adjusted OR 0.79, 95%CI 0.65-0.97), depression/anxiety (adjusted OR 0.91, 95%CI 0.86-0.95),
- dementia (adjusted OR 0.87, 95%CI 0.80-0.95), and osteoarthritis (adjusted OR 0.89, 95%CI 0.85-

- 200 0.93). The remaining long-term conditions (atrial fibrillation, COPD, asthma, chronic kidney disease,
- and cancer) were not associated with uncontrolled BP. (Figure 4)

202

203 Sensitivity analysis

- 204 Sensitivity analyses showed consistent results (Supplementary Tables S3, S4).
- In GEE models using \geq 130/80 mmHg as the threshold for sub-optimal blood pressure control, multimorbidity was still significantly associated with reduced likelihoods of uncontrolled BP (adjusted ORs 0.56, 95%CI 0.54-0.59), adjusting for age, sex, income quintiles, body mass index, and number of visits).
- 209 Discussion
- 210 Summary of findings

211 In this study, we aimed to investigate the association between multimorbidity and uncontrolled BP, 212 and to assess if individual long-term conditions are associated with uncontrolled BP. Our analysis in 213 67,385 Canadians aged 45 years or more with hypertension attending primary care from 2017 to 2019 214 showed an association between the presence of comorbidities and better blood pressure control. 215 Multimorbidity was associated with approximately 30% lower odds of uncontrolled BP. The 216 individual long-term conditions that were significantly associated with lower likelihood of uncontrolled BP include diabetes, heart failure, ischemic heart disease, schizophrenia, 217 218 depression/anxiety, dementia, or osteoarthritis.

219 *Comparison to the literature*

220 Our finding aligns with other studies that examined this association, which reported that 221 multimorbidity was one of the strongest predictors of controlled BP in patients with hypertension. 222 Tapela and colleagues found that multimorbidity was positively associated with BP control among 223 participants with hypertension in the UK Biobank, and the types of comorbidities that were 224 significantly associated with controlled BP included cardiovascular disease (OR 2.11, 95% CI 2.04 to

225 2.19), diabetes (OR 1.32, 95% CI 1.27 to 1.36), migraines (OR 1.68, 95% CI 1.56 to 1.81), and depression (OR 1.27, 95% CI 1.20 to 1.34).²⁸ Another study conducted by Sarkar and colleagues in 226 227 31,676 patients with hypertension in the Lambeth Data-Net, a patient-level primary care database in 228 the UK, found that 16,140 (51 %) had multimorbidity, and hypertensive patients with multimorbidity had lower BP than those with hypertension alone.¹². Mini and colleagues also reported that blood 229 230 pressure control was better in participants who reported any comorbidity (OR 2.37, 95%CI 1.51-3.71) compared to those who did not report any.¹⁶ However, several other studies reported the opposite 231 232 findings - people with more comorbidities had poorer management and control of hypertension. In a 233 study of 223,286 patients with hypertension in Hongkong, Wong et al. found that the proportion of 234 patients having poor BP control increased from 35.0% to 65.0% and 69.1% when the number of medical conditions increased from zero to one and two, respectively.¹⁵ However, this study enrolled 235 adult patients prescribed their first antihypertensive agents; hence people with comorbidities (such as 236 237 diabetes, heart failure, coronary heart disease) who were already on a relevant medication (beta-238 blockers, ACE inhibitors) for these reasons would be excluded from the hypertension cohort. A cross-239 sectional analysis of the World Health Organisation Study of Global Ageing and Adult Health (WHO 240 SAGE) Wave 1 (2007–10) in 41,557 adults (9778 with hypertension) from 6 middle-income countries 241 (including China, Ghana, India, Mexico, Russia and South Africa) reported that more comorbidities were associated with increased odds of uncontrolled hypertension.¹⁷ 242

The BP control rate in our study is also consistent with the literature. In a recent report from the NCD Risk Factor Collaboration using data from 1990 to 2019 on people aged 30–79 years from populationrepresentative studies with measurement of blood pressure, the estimated rate of uncontrolled BP in Canada was 25%-30% in 2019.²⁹ A report from the Danish General Practice Database of 37,651 patients with hypertension from 231 general practices showed that the overall BP control rate was 33.2%.¹⁸ A cross-sectional population-based study including 99,468 participants with hypertension enrolled in the UK Biobank reported that the overall control rate of BP was 38.1%.²⁸

250 Implication for practice and research

251 The results from this study may reflect the achievement of primary care in controlling cardiovascular 252 risk factors in patients with multimorbidity, including regular BP measures and treatment. 253 Comorbidities may be associated with more frequent healthcare utilisation and hence increase the 254 monitoring of chronic conditions, including BP measurement and counselling on lifestyle 255 modifications and medication adherence. Another explanation could be the study's participation 256 selection processes. Among people with hypertension as their only chronic health condition, those 257 with poorer BP control may be more motivated to attend primary care and hence were included in this 258 cohort. Thus, the observed associations could be explained by selection bias - hypertensive patients 259 with no comorbidities, but uncontrolled BP may have been more likely to seek primary care compared 260 to hypertensive patients with no comorbidities and controlled BP. These lead to opportunities to 261 measure BP and obtain scripts, reminders given to them on taking medications, and better lifestyle 262 modifications. More studies are needed to explore the mechanisms underlying the associations 263 between multimorbidity and BP control. 264 Strengths and limitations 265 This is one of the largest analyses of hypertension control in adults attending primary care in Canada, 266 with comprehensive sociodemographic and high-quality detailed clinical information, including 267 comorbidities. However, the data was only collected from patients in Ontario and is not nationally 268 representative. Another limitation of this study is that EMR data may be incomplete, and we might be 269 unable to capture all cases of hypertension and/or prescriptions of anti-hypertensive medications. 270 Lifestyle modification, which is an essential strategy in the management of hypertension and can 271 influence BP control, could not be captured through the EMR data. Duration and severity of 272 hypertension and other chronic diseases were also not captured. Therefore, results should be 273 replicated and cautiously interpreted before generalizing to all patients in primary care. 274 Conclusion 275 In this large-scale study of patients attending primary care with hypertension, multimorbidity was

associated with better BP control. Several long-term conditions were associated with better control,

277 including diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia,

and osteoarthritis. Further large-scale mixed methods studies are needed to explore the mechanisms

279	underlying the associations between multimorbidity and BP control, and to understand barriers to BP
280	control in primary care.

281

Acknowledgements. Dr Tu Nguyen is supported by the University of Sydney Global Development
Awards.

284 **References**

- 285 1. Oliveros E, Patel H, Kyung S, et al. Hypertension in older adults: Assessment, management,
- and challenges. *Clinical Cardiology* 2019; **43**: 99-107.

287 2. Nguyen TN, Chow CK. Global and national high blood pressure burden and control. *The*288 *Lancet* 2021; **398**(10304): 932-3.

289 3. Sierra C. Hypertension and the Risk of Dementia. *Front Cardiovasc Med* 2020; 7: 5-.

290 4. Fortin M, Dubois MF, Hudon C, Soubhi H, Almirall J. Multimorbidity and quality of life: a

closer look. *Health and quality of life outcomes* 2007; **5**: 52.

5. Skou ST, Mair FS, Fortin M, et al. Multimorbidity. *Nat Rev Dis Primers* 2022; **8**(1): 48.

293 6. Kennard L, O'Shaughnessy KM. Treating hypertension in patients with medical
294 comorbidities. *BMJ* 2016; 352: i101.

295 7. Ofori-Asenso R, Chin KL, Curtis AJ, Zomer E, Zoungas S, Liew D. Recent Patterns of
296 Multimorbidity Among Older Adults in High-Income Countries. *Popul Health Manag* 2018.

Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health
 consequences, and implications for quality, care management, and costs. *Journal of general internal medicine* 2007; 22 Suppl 3: 391-5.

- Mokraoui NM, Haggerty J, Almirall J, Fortin M. Prevalence of self-reported multimorbidity
 in the general population and in primary care practices: a cross-sectional study. *BMC Res Notes* 2016;
 9: 314.
- Marina S-B, Mark A, Alessandra B, et al. Impact of multimorbidity on healthcare costs and
 utilisation: a systematic review of the UK literature. *British Journal of General Practice* 2021;
 71(702): e39.

306	11.	Rodrigues	LP,	de	Oliveira	Rezer	nde A	ΑT,	Delpino	FM,	et	al.	Association	betw	/een
307	multim	norbidity and	l hosp	oitali	zation in	older	adult	s: sy	stematic	review	/ an	nd r	neta-analysis.	Age	and
308	Ageing	2022: 51 (7)	: afac	155.											

- 309 12. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of
 310 multimorbidity in blood pressure control. *BMC family practice* 2015; 16: 98-.
- 311 13. Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and Blood Pressure Control in
- 312 37 651 Hypertensive Patients From Danish General Practice. Journal of the American Heart
 313 Association; 2(1): e004531.
- Tran J, Norton R, Canoy D, et al. Multi-morbidity and blood pressure trajectories in
 hypertensive patients: A multiple landmark cohort study. *PLoS medicine* 2021; 18(6): e1003674-e.
- 316 15. Wong MC, Wang HH, Cheung CS, et al. Factors associated with multimorbidity and its link
- with poor blood pressure control among 223,286 hypertensive patients. *Int J Cardiol* 2014; **177**(1):
- **318** 202-8.
- Mini G, Mohan M, Sarma P, Thankappan K. Multi-morbidity and blood pressure control:
 Results of a cross-sectional study among school teachers in Kerala, India. *Indian Journal of Public Health* 2021; 65(2): 190-3.
- 322 17. Sum G, Koh GC-H, Mercer SW, et al. Patients with more comorbidities have better detection
 323 of chronic conditions, but poorer management and control: findings from six middle-income
 324 countries. *BMC Public Health* 2020; **20**(1): 9.
- Baulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and blood pressure control in
 37 651 hypertensive patients from Danish general practice. *J Am Heart Assoc* 2012; 2(1): e004531.
- Tu K, Sodhi S, Kidd M et al. The University of Toronto Family Medicine Report: Caring for
 our Diverse Populations. Toronto, ON; 2020.
- 329 20. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of
 330 multimorbidity in blood pressure control. *BMC Family Practice* 2015; 16(1): 98.
- 331 21. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of
 332 prevalence studies on multimorbidity: toward a more uniform methodology. *Ann Fam Med* 2012;
- **10**(2): 142-51.

- 334 22. Kone AP, Mondor L, Maxwell C, Kabir US, Rosella LC, Wodchis WP. Rising burden of
- 335 multimorbidity and related socio-demographic factors: a repeated cross-sectional study of Ontarians.
- 336 *Can J Public Health* 2021; **112**(4): 737-47.
- 337 23. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic
- conditions: imperatives for research, policy, program, and practice. *Prev Chronic Dis* 2013; **10**: E66.
- 339 24. Statistics Canada. Postal CodeOM Conversion File (PCCF), Reference Guide 2017. .
- 340 <u>https://www150.statcan.gc.ca/n1/pub/92-154-g/92-154-g2017001-eng.htm</u> (accessed 01/11/2022.
- 341 25. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada's 2016 Canadian
- 342 Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis,
- 343 Assessment of Risk, Prevention, and Treatment of Hypertension. *Can J Cardiol* 2016; **32**(5): 569-88.
- 26. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of
- arterial hypertension. *Eur Heart J* 2018; **39**(33): 3021-104.
- 346 27. Whelton PK, Carey RM, Aronow WS, et al. 2017
- 347 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,
- 348 Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American
- 349 College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
- 350 *Hypertension* 2018; **71**(6): e13-e115.
- Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and
 determinants of hypertension control among almost 100 000 treated adults in the UK. *Open Heart*2021; 8(1): e001461.
- 29. Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 populationrepresentative studies with 104 million participants. *The Lancet* 2021; **398**(10304): 957-80.
- 357

358

360

361 Table 1: Patient characteristics

	Controlled BP (N=43303)	Uncontrolled BP (N=24082)	Overall (N=67385)
Age (years)		-	
Mean (SD)	70.3 (11.6)	69.6 (12.2)	70.1 (11.8)
Median [Min, Max]	70.0 [47.0, 111]	69.0 [47.0, 110]	70.0 [47.0, 111]
Age group (years)			
45-74 years	30562 (70.6%)	17256 (71.7%)	47818 (71.0%)
75-84 years	8927 (20.6%)	4486 (18.6%)	13413 (19.9%)
85+ years	3814 (8.8%)	2340 (9.7%)	6154 (9.1%)
Sex			
Female	22637 (52.3%)	13132 (54.5%)	35769 (53.1%)
Male	20666 (47.7%)	10950 (45.5%)	31616 (46.9%)
Income Quintiles			
1 (low income)	8984 (20.7%)	5090 (21.1%)	14074 (20.9%)
2	7812 (18.0%)	4328 (18.0%)	12140 (18.0%)
3	7264 (16.8%)	3938 (16.4%)	11202 (16.6%)
4	7572 (17.5%)	4177 (17.3%)	11749 (17.4%)
5 (high income)	10693 (24.7%)	5976 (24.8%)	16669 (24.7%)
Missing	978 (2.3%)	573 (2.4%)	1551 (2.3%)
Multimorbidity			
No	7473 (17.3%)	5574 (23.1%)	13047 (19.4%)

	Controlled BP (N=43303)	Uncontrolled BP (N=24082)	Overall (N=67385)
Yes	35830 (82.7%)	18508 (76.9%)	54338 (80.6%)
Body mass index level			
Missing	7831 (18.1%)	5018 (20.8%)	12849 (19.1%)
18.4 or less (Underweight)	267 (0.6%)	145 (0.6%)	412 (0.6%)
18.5 - 24.9 (Normal)	6453 (14.9%)	3220 (13.4%)	9673 (14.4%)
25 - 29.9 (Overweight)	13470 (31.1%)	6999 (29.1%)	20469 (30.4%)
30 - 34.9 (Obese Class I)	9278 (21.4%)	5095 (21.2%)	14373 (21.3%)
35 - 39.9 (Obese Class II)	3782 (8.7%)	2208 (9.2%)	5990 (8.9%)
40 or more (Obese Class III)	2222 (5.1%)	1397 (5.8%)	3619 (5.4%)
Most recent smoking status			
Missing	11062 (25.5%)	6740 (28.0%)	17802 (26.4%)
Current	4219 (9.7%)	2542 (10.6%)	6761 (10.0%)
Non-Smoker	19999 (46.2%)	10868 (45.1%)	30867 (45.8%)
Past	8023 (18.5%)	3932 (16.3%)	11955 (17.7%)
Cancer			
No	37881 (87.5%)	21349 (88.7%)	59230 (87.9%)
Yes	5422 (12.5%)	2733 (11.3%)	8155 (12.1%)
Ischemic Heart disease			
No	37182 (85.9%)	21679 (90.0%)	58861 (87.4%)
Yes	6121 (14.1%)	2403 (10.0%)	8524 (12.6%)
Haart failura			

	Controlled BP (N=43303)	Uncontrolled BP (N=24082)	Overall (N=67385)
No	40754 (94.1%)	23082 (95.8%)	63836 (94.7%)
Yes	2549 (5.9%)	1000 (4.2%)	3549 (5.3%)
Atrial fibrillation			
No	38362 (88.6%)	21878 (90.8%)	60240 (89.4%)
Yes	4941 (11.4%)	2204 (9.2%)	7145 (10.6%)
Diabetes Mellitus			
No	28126 (65.0%)	17210 (71.5%)	45336 (67.3%)
Yes	15177 (35.0%)	6872 (28.5%)	22049 (32.7%)
Chronic Kidney disease			
No	35292 (81.5%)	20021 (83.1%)	55313 (82.1%)
Yes	8011 (18.5%)	4061 (16.9%)	12072 (17.9%)
Chronic Obstructive Pulmonary Disease			
No	39365 (90.9%)	22197 (92.2%)	61562 (91.4%)
Yes	3938 (9.1%)	1885 (7.8%)	5823 (8.6%)
Osteoarthritis			
No	26654 (61.6%)	15500 (64.4%)	42154 (62.6%)
Yes	16649 (38.4%)	8582 (35.6%)	25231 (37.4%)
Dementia			
No	39774 (91.9%)	22422 (93.1%)	62196 (92.3%)
Yes	3529 (8.1%)	1660 (6.9%)	5189 (7.7%)
Depression and/or Anxiety			

		Controlled BP (N=43303)	Uncontrolled BP (N=24082)	Overall (N=67385)
	No	28943 (66.8%)	16728 (69.5%)	45671 (67.8%)
	Yes	14360 (33.2%)	7354 (30.5%)	21714 (32.2%)
	Schizophrenia			
	No	42726 (98.7%)	23853 (99.0%)	66579 (98.8%)
	Yes	577 (1.3%)	229 (1.0%)	806 (1.2%)
362	Comparisons between patients	with controlled and uncontro	lled BP were asses	ssed using Pearson chi-
363	square tests for categorical cov	ariates and two-sample t-tests	s for continuous co	ovariates. All p-values
364	< 0.001			
365				
366				
367				
368				
369				
370				
371				
372				
373				
374				
375				
376				







Figure 2: Percentage of patients with uncontrolled blood pressure

- - -



401 Figure 3: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to

402 patient characteristics. *Odds ratio >1 means a greater likelihood of uncontrolled blood pressure.

403 Models were adjusted for age, sex, income quintiles, smoking status, body mass index, and number of

404 visits.

410







428 Supplementary data

429

430 Figure S1: Directed acyclic graph for the effect of multi-morbidity on blood pressure control



431

432

433 Table S1: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to

434 patient characteristics

Туре	Contrast	Odds ratios	Upper	Lower	P-value
Unadjusted odds	Total number of primary care visits: 9+ visits v.s. 0-2 visits	0.73827	0.79546	0.68520	< 0.001
ratios					
Unadjusted odds	Total number of primary care visits: 6-8 visits v.s. 0-2	0.78719	0.83093	0.74576	< 0.001
ratios	visits				
Unadjusted odds	Total number of primary care visits: 3-5 visits v.s. 0-2	0.80753	0.83877	0.77746	< 0.001
ratios	visits				
Unadjusted odds	Smoking Status: Past v.s. Non Smoker	0.92141	0.96352	0.88113	< 0.001
ratios					
Unadjusted odds	Smoking Status: Current v.s. Non Smoker	1.01420	1.07104	0.96038	0.612
ratios					
Unadjusted odds	BMI level: 40 or more (Obese Class III) v.s. 18.5 - 24.9	1.20424	1.31402	1.10364	< 0.001

ratios	(Normal)				
Unadjusted odds	BMI level: 35 - 39.9 (Obese Class II) v.s. 18.5 - 24.9	1.12685	1.20470	1.05403	< 0.001
ratios	(Normal)				
Unadjusted odds	BMI level: 30 - 34.9 (Obese Class I) v.s. 18.5 - 24.9	1.07457	1.13840	1.01432	0.015
ratios	(Normal)				
Unadjusted odds	RMI level: 25 - 29.9 (Overweight) v.s. 18.5 - 24.9	1 03133	1.08717	0.97836	0.251
	OL D	1.05155	1.00/1/	0.97830	0.231
ratios	(Normal)				
Unadjusted odds	BMI level: 18.4 or less (Underweight) v.s. 18.5 - 24.9	1.11997	1.37281	0.91370	0.275
ratios	(Normal)				
Unadjusted odds	Income Quintiles: 4 v.s. 5	0.98538	1.03246	0.94044	0.536
ratios					
Unadjusted odds	Income Quintiles: 3 v.s. 5	0.97333	1.02475	0.92448	0.303
ratios					
Unadjusted odds	Income Quintiles: 2 v.s. 5	0.97613	1.02786	0.92701	0.359
ratios					
Unadjusted odds	Income Quintiles: 1 v.s. 5	0.97758	1.02763	0.92997	0.373
ratios					
Unadjusted odds	Sex: Male v.s. Female	0.91376	0.94975	0.87915	< 0.001
ratios					
Unadjusted odds	Age group: 75-84 years v.s. 85+ years	0.81139	0.86227	0.76352	< 0.001
ratios					
Unadjusted odds	Age group: 45-74 years v.s. 85+ years	0.88376	0.94439	0.82703	< 0.001
ratios					
Unadjusted odds	Multimorbidity: Yes v.s. No	0.69121	0.71972	0.66384	< 0.001
ratios					
Adjusted odds ratios	Total number of primary care visits: 9+ visits v.s. 0-2 visits	0.81565	0.89297	0.74502	< 0.001
Adjusted odds ratios	Total number of primary care visits: 6-8 visits v.s. 0-2	0.82926	0.88645	0.77576	< 0.001
	visits				
Adjusted odds ratios	Total number of primary care visits: 3-5 visits v.s. 0-2	0.81522	0.85468	0.77759	< 0.001
	visits				
Adjusted odds ratios	Smoking Status: Past v.s. Non Smoker	0.93085	0.97948	0.88463	0.006
Adjusted odds ratios	Smoking Status: Current v.s. Non Smoker	1.14532	1.22043	1.07484	< 0.001
Adjusted odds ratios	BMI level: 40 or more (Obese Class III) v.s. 18.5 - 24.9	1.33611	1.47065	1.21388	< 0.001
	(Normal)				
Adjusted odds ratios	BMI level: 35 - 39.9 (Obese Class II) v.s. 18.5 - 24.9	1.23587	1.34055	1.13938	< 0.001
	(Normal)				
Adjusted odds ratios	BMI level: 30 - 34.9 (Obese Class I) v.s. 18.5 - 24.9	1.15571	1.23387	1.08249	< 0.001

	(Normal)				
Adjusted odds ratios	BMI level: 25 - 29.9 (Overweight) v.s. 18.5 - 24.9	1.08476	1.15337	1.02024	0.009
	(Normal)				
Adjusted odds ratios	BMI level: 18.4 or less (Underweight) v.s. 18.5 - 24.9	1.03778	1.32207	0.81462	0.764
	(Normal)				
Adjusted odds ratios	Income Quintiles: 4 v.s. 5	0.96900	1.03199	0.90985	0.327
Adjusted odds ratios	Income Quintiles: 3 v.s. 5	0.96202	1.02630	0.90176	0.241
Adjusted odds ratios	Income Quintiles: 2 v.s. 5	0.98320	1.04831	0.92213	0.604
Adjusted odds ratios	Income Quintiles: 1 v.s. 5	1.00317	1.06821	0.94208	0.921
Adjusted odds ratios	Sex: Male v.s. Female	0.89949	0.93914	0.86152	< 0.001
Adjusted odds ratios	Age group: 75-84 years v.s. 85+ years	0.80118	0.87470	0.73384	<0.001
Adjusted odds ratios	Age group: 45-74 years v.s. 85+ years	0.77803	0.84269	0.71832	<0.001
Adjusted odds ratios	Multimorbidity: Yes v.s. No	0.71761	0.75742	0.67990	<0.001

435

436

437 Table S2: Mean number of primary care visits for patients with and without multi-morbidity

438

(annually)

Mean (standard deviation) number of primary	mult	imorbidity
care visits annually	No	Yes
2017	2.14 (2.17)	3.80 (3.44)
2018	2.30 (2.22)	3.88 (3.36)
2019	2.44 (2.19)	3.91 (3.28)
Frequen	cy (N, column %)	
	2017	
0-2 visits	8599	22134

	65.91	40.73
3-5 visits	3523	19794
	27.00	36.43
6-8 visits	729	7838
	5.59	14.42
9+ visits	196	4572
	1.50	8.41
	2018	I
0-2 visits	8219	21141
	63.00	38.91
3-5 visits	3813	20635
	29.23	37.98
6-8 visits	779	8143
	5.97	14.99
9+ visits	236	4419
	1.81	8.13
	2019	
0-2 visits	7934	20688
	60.81	38.07

3-5 visits	4024	21156
	30.84	38.93
6-8 visits	846	8145
	6.48	14.99
9+ visits	243	4349
	1.86	8.00

439

440 Table S3: Patient characteristics for sub-optimal blood pressure control (≥130/80 mmHg)

	Controlled BP	Uncontrolled BP	Overall	
	(N=19535)	(N=47850)	(N=67385)	P-value
Age (years)				
Mean (SD)	72.1 (11.5)	69.2 (11.9)	70.1 (11.8)	<0.001
Median [Min, Max]	72.0 [47.0, 111]	69.0 [47.0, 110]	70.0 [47.0, 111]	
Age group (years)				
45-74 years	12809 (65.6%)	35009 (73.2%)	47818 (71.0%)	<0.001
75-84 years	4597 (23.5%)	8816 (18.4%)	13413 (19.9%)	
85+ years	2129 (10.9%)	4025 (8.4%)	6154 (9.1%)	
Sex				
Female	10183 (52.1%)	25586 (53.5%)	35769 (53.1%)	0.00652
Male	9352 (47.9%)	22264 (46.5%)	31616 (46.9%)	
Income Quintiles				
1 (low income)	4259 (21.8%)	9815 (20.5%)	14074 (20.9%)	<0.001
2	3605 (18.5%)	8535 (17.8%)	12140 (18.0%)	

	Controlled BP	Uncontrolled BP	Overall	Duralua
	(N=19535)	(N=47850)	(N=67385)	P-value
3	3223 (16.5%)	7979 (16.7%)	11202 (16.6%)	
4	3323 (17.0%)	8426 (17.6%)	11749 (17.4%)	
5 (high income)	4626 (23.7%)	12043 (25.2%)	16669 (24.7%)	
Missing	499 (2.6%)	1052 (2.2%)	1551 (2.3%)	
Multimorbidity				
No	2528 (12.9%)	10519 (22.0%)	13047 (19.4%)	<0.001
Yes	17007 (87.1%)	37331 (78.0%)	54338 (80.6%)	
Body mass index level				
Missing	3347 (17.1%)	9502 (19.9%)	12849 (19.1%)	<0.001
18.4 or less (Underweight)	152 (0.8%)	260 (0.5%)	412 (0.6%)	
18.5 - 24.9 (Normal)	3226 (16.5%)	6447 (13.5%)	9673 (14.4%)	
25 - 29.9 (Overweight)	6190 (31.7%)	14279 (29.8%)	20469 (30.4%)	
30 - 34.9 (Obese Class I)	4043 (20.7%)	10330 (21.6%)	14373 (21.3%)	
35 - 39.9 (Obese Class II)	1630 (8.3%)	4360 (9.1%)	5990 (8.9%)	
40 or more (Obese Class III)	947 (4.8%)	2672 (5.6%)	3619 (5.4%)	
Most recent smoking status				
Missing	4935 (25.3%)	12867 (26.9%)	17802 (26.4%)	<0.001
Current	1909 (9.8%)	4852 (10.1%)	6761 (10.0%)	
Non Smoker	8856 (45.3%)	22011 (46.0%)	30867 (45.8%)	
Past	3835 (19.6%)	8120 (17.0%)	11955 (17.7%)	
Cancer				
No	16955 (86.8%)	42275 (88.3%)	59230 (87.9%)	<0.001
Yes	2580 (13.2%)	5575 (11.7%)	8155 (12.1%)	
Ischemic Heart disease				
No	16032 (82.1%)	42829 (89.5%)	58861 (87.4%)	<0.001

	Controlled BP	Uncontrolled BP	Overall	Durahua
	(N=19535)	(N=47850)	(N=67385)	P-value
Yes	3503 (17.9%)	5021 (10.5%)	8524 (12.6%)	•
Heart failure				
No	18006 (92.2%)	45830 (95.8%)	63836 (94.7%)	<0.001
Yes	1529 (7.8%)	2020 (4.2%)	3549 (5.3%)	
Atrial fibrillation				
No	16799 (86.0%)	43441 (90.8%)	60240 (89.4%)	<0.001
Yes	2736 (14.0%)	4409 (9.2%)	7145 (10.6%)	
Diabetes Mellitus				
No	11842 (60.6%)	33494 (70.0%)	45336 (67.3%)	<0.001
Yes	7693 (39.4%)	14356 (30.0%)	22049 (32.7%)	
Chronic Kidney disease				
No	15193 (77.8%)	40120 (83.8%)	55313 (82.1%)	<0.001
Yes	4342 (22.2%)	7730 (16.2%)	12072 (17.9%)	
Chronic Obstructive Pulmonary Disease				
No	17487 (89.5%)	44075 (92.1%)	61562 (91.4%)	<0.001
Yes	2048 (10.5%)	3775 (7.9%)	5823 (8.6%)	
Mental health				
No	11804 (60.4%)	30997 (64.8%)	42801 (63.5%)	<0.001
Yes	7731 (39.6%)	16853 (35.2%)	24584 (36.5%)	

Table S4: Adjusted odds ratios using GEE model for sensitivity analysis using ≥ 130/80 mmHg as

445 the threshold for sub-optimal blood pressure control.

Contrast	Adjusted odds ratios	Lower	Upper	P-value
Multimorbidity: Yes vs. No	0.56	0.54	0.59	<0.001
Age group: 45-74 years vs. 85+ years	1.29	1.22	1.37	<0.001
Age group: 75-84 years vs. 85+ years	0.98	0.92	1.05	0.582
Sex: Male vs. Female	0.91	0.88	0.94	<0.001
Income Quintiles: 1 vs. 5	0.93	0.88	0.98	0.005
Income Quintiles: 2 vs. 5	0.95	0.90	1.00	0.062
Income Quintiles: 3 vs. 5	0.97	0.92	1.02	0.34
Income Quintiles: 4 vs. 5	0.98	0.93	1.03	0.405
Region: Urban vs. Rural	0.84	0.78	0.90	<0.001

446

447

448

449 Table S5: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to co-

450 morbidities

Туре	Contrast	Odd ratios	Lower	Upper	P-Value
Unadjusted odds ratios	Ischemic Heart Disease: Yes vs. No	0.66969	0.63707	0.70399	< 0.001
Unadjusted odds ratios	Heart Failure: Yes vs. No	0.71025	0.65731	0.76745	< 0.001
Unadjusted odds ratios	Atrial Fibrillation: Yes vs. No	0.79316	0.75169	0.83692	< 0.001
Unadjusted odds ratios	Diabetes Mellitus: Yes vs. No	0.73233	0.70360	0.76223	< 0.001
Unadjusted odds ratios	Chronic Obstructive Pulmonary Disease: Yes vs. No	0.82250	0.77670	0.87100	< 0.001
Unadjusted odds ratios	Chronic Kidney Disease: Yes vs. No	0.90107	0.86078	0.94326	< 0.001
Unadjusted odds ratios	Osteoarthritis: Yes vs. No	0.88485	0.85331	0.91755	< 0.001
Unadjusted odds ratios	Cancer: Yes vs. No	0.88660	0.84844	0.92646	< 0.001
Unadjusted odds ratios	Dementia: Yes vs. No	0.85688	0.80274	0.91466	< 0.001
Unadjusted odds ratios	Depression and/or Anxiety: Yes vs. No	0.87679	0.84454	0.91028	< 0.001
Unadjusted odds ratios	Schizophrenia: Yes vs. No	0.78581	0.67154	0.91952	< 0.001

Adjusted odds ratios	Ischemic Heart Disease: Yes vs. No	0.73727	0.68770	0.79041	< 0.001
Adjusted odds ratios	Heart Failure: Yes vs. No	0.81404	0.72606	0.91268	< 0.001
Adjusted odds ratios	Atrial Fibrillation: Yes vs. No	0.92968	0.86071	1.00417	0.064
Adjusted odds ratios	Diabetes Mellitus: Yes vs. No	0.73368	0.70013	0.76885	< 0.001
Adjusted odds ratios	Chronic Obstructive Pulmonary Disease: Yes vs. No	0.98163	0.90611	1.06344	0.65
Adjusted odds ratios	Chronic Kidney Disease: Yes vs. No	0.94286	0.88606	1.00330	0.063
Adjusted odds ratios	Osteoarthritis: Yes vs. No	0.88625	0.84715	0.92716	< 0.001
Adjusted odds ratios	Cancer: Yes vs. No	0.95232	0.89199	1.01672	0.143
Adjusted odds ratios	Dementia: Yes vs. No	0.86759	0.79505	0.94675	0.001
Adjusted odds ratios	Depression and/or Anxiety: Yes vs. No	0.90557	0.86453	0.94856	< 0.001
Adjusted odds ratios	Schizophrenia: Yes vs. No	0.79424	0.65170	0.96795	0.022

452

453

454

455

456

457 Appendix

- 458 The appendix section contains the following sections:
- 459 i) Drug names for different classes of hypertension medications;
- 460 ii) Definition for the hypertension phenotype;
- 461 iii) Definition for primary care visit in UTOPIAN database;

462

463

464

466	
467	
468	
469	
470	
471	
472	
473	
474	
475	
476	
477	
478	Hypertension medication classes

479 The following search criteria were used to identify hypertension medication:

Drug class	Search criteria
name	
ACE	%medication(in=ACE,
inhibitors	
	search='benazepril Lotensin captopril Capoten Captotec Captril cilazapril Inhib
	ace Inhibase enalapril Vasotec fosinopril Monopril lisinopril Zestril Prinivil per
	indopril Coversyl quinapril

	hcl Accupril Accupro ramipril Altace trandolapril Mavik');
ARB inhibitors	%medication(in=ARB,
	search='candesartan Atacand eprosartan Teveten irbesartan Avapro losartan Cozaar olmesartan Olmetec telmisartan Micardis valsartan Diovan');
Calcium channels	%medication(in=Ca_channel,
	search='amlodipine Norvasc diltiazem Cardizem Tiazac felodipine Renedil Plen dil nicardipine Cardene nifedipine Adalat nimodipine Minotop verapamil Isop tin Veralan Veramil');
Beta- blockers	%medication(in=beta_blockers,
	search='acebutolol Monitan Sectral Rhotral atenolol Tenormin bisoprolol Mon ocor labetalol Trandate metoprolol Lopressor Toprol Betaloc nadolol Corgard oxprenolol Trasicor pindolol Visken propranolol Inderal Detensol');
Diuretics	%medication(in=diuretics.
	search='amiloride Midamor spironolactone Aldactone triamterene Neo Diurex chlortalidone Thiazide Hygroton hydrochlorothiazide Oretic Microzide

	Diuchlor H Esidrix Hydro Aquil Hydrodiuril Neo Codema Urozide Apo-
	Hydro indapamide Lozide');
Other classes	******
of	
hypertension	Others includes
medication	- Renin Inhibitor
	- Alpha-2 Adrenergic Receptor Agonist
	- combination medications

	% medication (in=others,
	search=
	'aliskiren Basilez clonidine Catapres Catapresan Kapvay Dixarit methyldopa D
	opazide Methazide Doparil
	benazepril & hydrochlorothiazide Lotensin
	cilazapril & hydrochlorothiazide Inhibace Plus
	enalapril & hydrochlorothiazide Vaseretic
	ramipril & hydrochlorothiazide Altace HCT
	lisinopril & hydrochlorothiazide Zestoretic Prinzide
	perindopril & indapamide Coversyl Plus
	perindopril & amlodipine Viacoram

quinapril & hydrochlorothiazide Accuretic
amlodipine & telmisartan Twynsta
azilsartan & chlortalidone Edarbyclor
eprosartan & hydrochlorothiazide Teveten Plus
candesartan & hydrochlorothiazide Atacand Plus
hydrochlorothiazide & irbesartan Avalide
hydrochlorothiazide & losartan Hyzaar
hydrochlorothiazide & olmesartan Benicar HCT Olmetec Plus
valsartan & hydrochlorothiazide Diovan HCT
losartan & hydrochlorothiazide Hyzaar
telmisartan & hydrochlorothiazide Micardis HCT Micardis Plus
valsartan & sacubitril Entresto
atenolol & chlortalidone Tenoretic
atenolol & hydrochlorothiazide
felodipine & metoprolol Logimat Mibloc Mobloc Logimax Forte Mobloc Forte
nadolol & bendroflumethiazide Corzide
pindolol & hydrochlorothiazide Viskazide
propranolol & hydrochlorothiazide Inderide
timolol & hydrochlorothiazide Timolide
felodipine & ramipril Inotens Unimest And Unitens

verapamil & trandolapril Tarka
chlortalidone & reserpine Regroton
methyldopa & hydrochlorothiazide Aldoclor Aldoril
clonidine & chlortalidone Clorpres Combipres
reserpine & hydrochlorothiazide Hydroserpine Hydropres Serpasil Esidrix
reserpine & hydrochlorothiazide hydralazine hcl Ser-Ap-ES Serpazide Uni
Serp Hydrap-Es Diuretic-Ap-Es Marpres Serathide Unipres Serpex
metoprolol & hydrochlorothiazide Dutoprol Lopressor HCT
metoprolol & chlortalidone Lopressidone Logroton
amiloride & hydrochlorothiazide Amiloride HCTZ Amihydro Riva-
Amilzide Amilazide Amilzide Atenidone Moduretic
spironolactone & hydrochlorothiazide Aldactazide Spirozide Spirozine
triamterene & hydrochlorothiazide Dyazide Maxzide Diazide Pro
Triazide Triamzide Riva-Zide Triazide Hydro-Triam');

481

480

482

483 Hypertension phenotype

484

485 We defined the hypertension phenotype using the following criteria:

- 486 1. Free text documentation of hypertension in the past or present health condition section of
- 487 the cumulative patient included at least one of the following terms:

488	Include	Do not include
489	Hypertension	Hypertensive response
490	Hypertensive	Borderline
491	Htn	Occular/ocular
492		Maternal
493		Gestation
494		White coat
495		Pulmonary
496		Pregnancy induced/PIH
497	2. Anti-ł	hypertensive medication (listed above) was prescribed and an elevated blood pressure
498	readi	ng was recorded at any point in the EMR
499	a. eleva	ted blood pressure reading is defined as systolic blood pressure >= 140 mmHg or
500	diasto	olic blood pressure >= 90 mmHg
501	OR	
502	3. Anti-ł	hypertensive medication (listed above) was prescribed and a billing record with the
503	diagn	osis code for hypertension (401) was found at any point in the EMR
504	OR	

- 505 4. A billing record with the diagnosis code for hypertension (401) was found and an elevated
- 506 blood pressure reading was recorded at any point in the EMR
- 507 a. elevated blood pressure reading is defined as systolic blood pressure >= 140 mmHg or
- 508 diastolic blood pressure >= 90 mmHg
- 509

510 Definition for primary care visit in UTOPIAN database

- 511 OHIP service codes billed during the study period (Jan 2017 to Dec 2019) were used to select family
- 512 physician visits that occurred via telephone, video, or in-person. Billing records for eligible patients
- 513 containing any of the following service codes were counted as family physician visits:

Code	Description	Code	Description
A001	minor assessment	K017	periodic health visit-child aft. 2nd birthday
A002	enhanced 18-month well baby visit	K022	hiv prim care individ care 1/2 hr or major part
A003	major assessment	K028	sexually transmitted disease (std) counseling
A004	general re-assessment	K030	diabetic management fee
A007	intermediate assessment	K032	gp-specific neurocognitive assessment
A008	mini assessment	K033	counselling - 1 pt/yr/unit
A071	complex medical specific re- assessment	K039	smoking cessation follow-up visit
A131	complex medical specific re- assessment	K130	periodic health visit - adolescent

A134	medical specific re-assessment	K131	periodic health visit - adult aged 18 to 64 inclusive
A624	medical specific re-assessment	K132	periodic health visit - adult 65 years of age and older
A888	partial assessment		substance abuse - extended assessment
A903	pre-op assessment	P003	obsprenatal care-gen.assess-major prenatal visit
A920	medical management of early pregnancy, initial visit	P004	obsprenatal care-minor prenatal assesssubseq.prenat.vis.
К005	primary mental health	P005	antenatal health screen
K007	ind. psychotherapy per half hour - gp	P008	obspost-natal care in office
К013	counselling-one or more people-per 1/2hr	К037	fibromyalgia/chronic fatigue syndrome care
K080	Minor assessment of patient by telephone or video	K081	Intermediate assessment including psychotherapy by telephone or video
K082	Psychotherapy, psychiatric or mental health counselling by telephone or video	K087	Minor assessment of an uninsured by telephone or video
K088	Intermediate assessment of an uninsured patient including psychotherapy by telephone or video	K089	Psychotherapy, psychiatric or mental health counselling of an uninsured patient by telephone or video